Global Trypsin Market is segmented By Type( Bovine Trypsin, Porcine Trypsin), By Application ( Industrial Use, Medicine, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The global "trypsin market" size is estimated to reach at a high CAGR during the forecast period 2022-2029
Trypsin, a serine protease from the PA superfamily, hydrolyzes proteins in many vertebrate digestive systems. When the proenzyme form of trypsin, pancreatic trypsinogen, is activated in the small intestine, trypsin is produced.
Market Dynamics
The factors driving the growth of the global trypsin market are the increasing use of trypsin in industrial applications, medicine, and other industries.
The increasing use of trypsin in industrial applications, medicine, and other industries is expected to drive the market
Trypsin is widely used in the leather bating, detergent, food, and pharmaceutical industries. Trypsin was used in insulin production to convert the insulin precursor into insulin ester by digesting the mini-C-peptide. Trypsin was used in food processing to prepare healthy proteins/peptides, reducing allergenicity and increasing the digestibility of baby food. In the pharmaceutical industry, trypsin has also been studied for its wound healing properties. Commercial trypsin is currently extracted from the porcine and bovine pancreas. On the other hand, animal-derived trypsin is strictly controlled in pharmaceutical and food manufacturing due to the potential risk of contamination with infectious agents. Thus, microbial Streptomyces griseus trypsin (SGT) is a potential alternative with a three-dimensional structure and catalytic activity like bovine trypsin (BT).
The primary function of trypsin and chymotrypsin in the human body is protein digestion. These naturally occurring pancreatic proteins play an important role in the human body's digestion of food. Because of this functional property, they are effective when used in food applications to hydrolyze proteins. Trypsin has a wide range of applications due to its fundamental physiological function, the same as the human digestive system. It is useful in foods, pharmaceuticals, tissue dissociation, cell harvesting, and microbiological media.
Side effects associated with trypsin is expected to hamper the market growth
Trypsin and chymotrypsin can cause shivering, hepatic damage, necrotic damage, and cardiac arrhythmia during the recovery stage. Although trypsin did not cause any side effects when combined with other digestive enzymes, there have not been enough reports of trypsin (taken alone by mouth) and its safety level.
When applied to the skin for wound treatment, trypsin can cause mild side effects such as local pain and a temporary burning sensation. Over-the-counter enzymes that are taken orally have been linked to GI distress, particularly at high doses. A few reports of severe allergic reactions, known as anaphylaxis, linked to oral chymotrypsin. Anaphylaxis symptoms are considered a medical emergency and may include breathing difficulties or noisy breath sounds, inflammation of the tongue or throat, throat constriction, talking is difficult (hoarse voice), wheezing, coughing, dizziness, collapse.
Industry Analysis
Supply Chain Analysis:
Porter's Five Forces Analysis:
COVID-19 Impact Analysis
AAT (Alpha-1 Antitrypsin Therapy) therapy, an FDA-approved drug, is currently the only available pharmacological treatment to slow COPD progression in patients with AATD (Alpha-1 Antitrypsin Deficiency). COPD is a respiratory disease marked by persistent respiratory symptoms, significant airflow obstruction, and increased lung and systemic inflammation. AAT given intravenously or inhaled has been used in multiple clinical trials for chronic obstructive pulmonary disease or cystic fibrosis, and it has a favorable safety profile. AAT has been shown to inhibit TMPRSS2 in the context of hepatitis C virus infection. Previous findings from COVID-19 patients indicated a relative deficiency of AAT in relation to inflammatory markers. Hence, with an increase in COPD disease with COVID-19 cases, the trypsin market is impacted.
Segment Analysis
The bovine trypsin segment is expected to dominate the global trypsin market
The enzyme PDB 1AQ7 bovine trypsin is complexed with the inhibitor aeruginosin 98-B. Aeruginosin inhibits trypsin in a manner similar to that of a typical serpin, except that it does not come into direct contact with the catalytic triad of Ser-195, His-57, and Asp-102. Instead, there is a water-mediated interaction at the end of bound aeruginosin 98-B between the hydroxyl of (4-hydroxy) phenyllactic acid, the amide NH of Cys-220, and the carbonyl oxygen of Ser-146. Aeruginosin uses water to extend its binding interactions. Bovine Recombinant Trypsin is derived from neither animals nor humans. Trypsin Bovine cleaves peptide bonds specifically after basic amino acids such as lysine and arginine.
Many attempts to express bovine trypsin in alternative platforms have resulted from the industry's growing desire to avoid reagents derived from animals. As a result, Woodard et al. developed and optimized trypsin expression in maize for large-scale industrial and pharmaceutical applications. To complete the task, the enzyme was expressed in an inactive zymogen form that accumulates in the endosperm of maize seeds. The zymogen gene was inserted into maize plants, which were then grown in open fields. Sigma-Aldrich currently sells the purified enzyme under the brand name TrypZean. While it is more expensive than animal-derived trypsin, the cost is more than offset by the elimination of regulatory costs associated with viral-clearance studies, which are required when using the animal product.
Geographical Analysis
North America region is expected to hold the largest market share in the global trypsin market
The increasing research & development and presence of key players are expected to drive this region's market. For instance, the presence of trypsin inhibitors in the leaves of four important North American prairie grasses (Agropyron smithii, Andropogon gerardii, Agropyron scoparius, and Bouteloua gracilis) was investigated. Young leaves of A. Smithii had higher inhibitory activity than old leaves, but no differences in leafage were found in B. gracilis. Mechanical wounding of A. Smithii leaves resulted in no consistent increase in inhibitor activity, contrary to reports for other plant species. Trypsin inhibitor levels in A. smithii plants collected from heavily grazed prairie dog areas were comparable to those in plants collected from a grazing exclosure. As a result, the ecological role of proteinase inhibitors in these Great Plains dominants remains unknown.
Thermo Fisher Scientific, a company based in the U.S, manufactures Gibco Trypsin (1:250) powder. The powder is an irradiated mixture of porcine pancreas proteases.
Hence, with the increasing research and investigations, the presence of major key players in this region is expected to drive market growth.
Competitive Landscape
The global trypsin market is moderately competitive with company mergers and acquisitions. Some of the key players in the market are Neova Technologies, BIOZYM, Bovogen Biologicals, BBI Solutions, Geyuantianrun Biotech, Deebiotech, Linzyme Biosciences, Hawkins, Inc. Pharmaceutical Group, Biolaxi Corporation,
BBI Solutions
Overview: BBI Solutions is a producer of immuno-diagnostics reagents, has been serving the global diagnostics industry for over 50 years.
A comprehensive suite of reagents with custom development options, lateral flow development, diagnostic manufacturing services, and smartphone reader technologies are their core products.
Product Portfolio: The company manufactures Trypsin >0.5 µKatal/mg source Bovine pancreas. BBI Solutions (BBI) is a high-quality Trypsin manufacturer. For over 40 years, the company's team in Cape Town has been producing Trypsin under a quality system that meets the latest ISO 13485:2016 standard requirements.
Key Development: On 17 June 2021, Novo Holdings acquired BBI Group. The investment in BBI by Novo Holdings is part of the company's primary investment strategy, which focuses on well-established life science companies with leading positions in attractive market segments and strong underlying growth drivers.
